晨光生物(300138.SZ):近日正式取得8項專利證書
格隆匯8月16日丨晨光生物(300138.SZ)公佈,公司及子公司——邯鄲晨光珍品油脂有限公司(“晨光珍品油脂”)於近日正式取得了國家知識產權局頒發的八項專利證書,具體情況如下:

以上專利主要是克服現有技術中的不足,對現有工藝進行的改進和提升,其中“一種製備高純度低危害的番茄紅素晶體的方法”、“一種工業化提取萬壽菊黃酮的方法及其萬壽菊黃酮”、“ 一種生產高品質水飛薊素的工業化方法”、“一種防止串流的拖鏈式浸出器”和“一種共軛亞油酸的生產方法”已應用於生產,其他專利將陸續應用於生產經營。上述專利的取得,有利於發揮公司的自主知識產權優勢,形成持續創新機制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.